Structural And Functional Consequences Of Left Ventricular Hypertrophy Regression.
Funder
National Health and Medical Research Council
Funding Amount
$293,036.00
Summary
Left ventricular hypertrophy (LVH) is a thickening of the heart muscle walls that occurs in a variety of cardiovascular diseases, including high blood pressure, coronary artery disease, cardiac valve disorders and heart dilatation. The presence of LVH increases the risk of developing heart attacks, heart failure and death. Treatment of these disorders is a major component of our escalating health-care costs. Consequently, reversal of LVH may have significant benefits to individual patients and s ....Left ventricular hypertrophy (LVH) is a thickening of the heart muscle walls that occurs in a variety of cardiovascular diseases, including high blood pressure, coronary artery disease, cardiac valve disorders and heart dilatation. The presence of LVH increases the risk of developing heart attacks, heart failure and death. Treatment of these disorders is a major component of our escalating health-care costs. Consequently, reversal of LVH may have significant benefits to individual patients and society in general. We propose to develop a mouse model of an inherited form of LVH that is caused by gene mutations in heart muscle proteins. This model will enable us to study in detail the disease processes that cause LVH and the effects of reversing LVH. This information will be invaluable for determining the best ways of treating patients with LVH.Read moreRead less
Regulatory Pathways Of Compensatory Left Ventricular Hypertrophy
Funder
National Health and Medical Research Council
Funding Amount
$309,536.00
Summary
An increase in muscle bulk (hypertrophy) of the major pumping chamber of the heart, the left ventricle, occurs as a compensatory mechanism to maintain cardiac function in a wide variety of common cardiovascular diseases, such as hypertension. Nevertheless, this compensatory mechanism appears to be strongly associated with an increased risk of death from cardiovascular disease. Consequently, the prevention or reversal of left ventricular hypertrophy is one of the major goals of the treatment of p ....An increase in muscle bulk (hypertrophy) of the major pumping chamber of the heart, the left ventricle, occurs as a compensatory mechanism to maintain cardiac function in a wide variety of common cardiovascular diseases, such as hypertension. Nevertheless, this compensatory mechanism appears to be strongly associated with an increased risk of death from cardiovascular disease. Consequently, the prevention or reversal of left ventricular hypertrophy is one of the major goals of the treatment of patients with cardiovascular disease. This project aims to improve our understanding of the complex chemical messengers in the heart muscle that control the development of hypertrophy to provide a basis for more specific drug treatments to control this process, with the aim of reducing the morbidity and mortality associated with hypertrophy.Read moreRead less
Benefit Of 2D-strain Surveillance In Improving Cardiovascular Outcomes In Cancer Patients Undergoing Cardiotoxic Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$2,391,979.00
Summary
Cancer survivors are susceptible to heart failure (HF) caused by heart muscle damage from chemotherapy. The current testing for this problem is based on a measure that cannot identify minor changes of cardiac function. Cardiac strain is a sensitive new marker of cardiac function which is predictive of overt dysfunction & HF. This study seeks to identify whether strain can be used to assign treatments that lead to improved cardiac function and are eventually associated with a reduction in HF.
Clinical Utility Of New Non-invasive Assessments Of Left Ventricular Function.
Funder
National Health and Medical Research Council
Funding Amount
$48,361.00
Summary
This project involves a series of studies that investigate the use of new ultrasound measurements of heart function in order to assess whether or nor they make a meaningful contribution to patient management, both in terms of diagnosis and monitoring of treatments. Major studies include: 1) Detection and prevention of early heart disease in patients who are undergoing toxic chemotherapy for cancer; and 2) Investigation and treatment of patients with a high blood pressure response to exercise.
I am a cardiology research scientist investigating the differences between physiological (“good”) and pathological (“bad”) heart growth- cardiac hypertrophy. In general, heart failure research and therapy has concentrated on identifying and inhibiting pathological processes. In contrast, my research is unique because it has focused on activating physiological pathways (elevated in the athlete’s heart) in the failing heart as a potential new strategy for the treatment of heart failure and atrial ....I am a cardiology research scientist investigating the differences between physiological (“good”) and pathological (“bad”) heart growth- cardiac hypertrophy. In general, heart failure research and therapy has concentrated on identifying and inhibiting pathological processes. In contrast, my research is unique because it has focused on activating physiological pathways (elevated in the athlete’s heart) in the failing heart as a potential new strategy for the treatment of heart failure and atrial fibrillation.Read moreRead less
NOVEL CGMP-BASED THERAPIES PREVENT LEFT VENTRICULAR REMODELLING
Funder
National Health and Medical Research Council
Funding Amount
$533,433.00
Summary
Over 300,000 Australians are affected by heart failure. Current drugs for cardiac remodelling (the decline in heart pumping function and changed structure that precede heart failure) slow but not reverse disease progression. We have identified a new, nitrovasodilator-based therapy superior to those currently available. We propose it represents a more effective treatment for reversing abnormalities in both structure and function in the remodelled heart, preventing or delaying heart failure.
Formyl Peptide Receptor Biased Agonists As Novel Cardioprotection From Myocardial Infarction
Funder
National Health and Medical Research Council
Funding Amount
$948,291.00
Summary
Heart attack is caused by a blocked heart blood vessel. Current therapy focuses on rapid reopening of the vessel, to allow blood supply to return. However, even if this is successful, affected patients are often left with impaired heart muscle pumping function, ultimately progressing to heart failure. We have discovered an exciting new mechanism to protect heart muscle from injury and preserve its function, and we plan to develop new drugs for heart attack based on this mechanism.
Prediction Of Ventricular Arrhythmias And Prevention Of Sudden Cardiac Death Following Revascularised Acute Myocardial Infarction.
Funder
National Health and Medical Research Council
Funding Amount
$117,270.00
Summary
Acute myocardial infarction (AMI) is a leading cause of death in Australia. Patients with coronary artery disease and impaired left ventricular function are at increased risk of heart failure, reinfarction and sudden cardiac death (SCD). This research will evaluate optimal methods to identify patients at risk for SCD following AMI using echocardiographic, MRI, and electrophysiological characteristics, and improve survival by early identification and management of these high-risk patients.
TARGETING ROS-INDUCED DAMAGE RESCUES THE DIABETIC HEART
Funder
National Health and Medical Research Council
Funding Amount
$487,669.00
Summary
Over 1 million Australians have diabetes. Many of these patients die from cardiovascular disease. We have identified free radicals as a major cause of decreased pumping function and impaired recovery from each heartbeat in the diabetic heart. Stronger antioxidant approaches and-or activation of protective protein pathways is a more effective treatment for reversing impaired function in the diabetic heart, preventing or delaying heart failure in patients with diabetes.
Value Of Central Blood Pressure For GUIDing ManagEment Of Hypertension (BP GUIDE Study)
Funder
National Health and Medical Research Council
Funding Amount
$339,553.00
Summary
A pressure pulse may be felt at the wrist with every heart beat. New technology allows the analysis of this pulse and measurement of blood pressure (BP) at the heart (central BP) . This information may help doctors improve the decision making process regarding a patient's risk related to BP as well as the effect of drug treatment. The study aims to test this theory. It is expected that the new technology will improve the way people with high BP are identified and treated.